logo-loader
Amryt Pharma PLC

Amryt soars as US bankruptcy court clears way for Aegerion acquisition

Orphan drug firm Amryt said it would acquire Aegerion once the approved plan of reorganisation came into effect on or around 24 September

Amryt Pharma PLC - Amryt soars as US bankruptcy court clears way for Aegerion acquisition

Amryt Pharma PLC (LON:AMYT) shares bounced on Wednesday after a ruling from the US bankruptcy court cleared the way for its acquisition of Aegerion Pharmaceuticals Inc.

Orphan drug firm Amryt said once the approved plan of reorganisation came into effect, around 24 September, it would acquire Aegerion in exchange for its own stock, which would be distributed to certain creditors of the US firm.

WATCH: Amryt Pharma co-founder welcomes 'transformational' Aegerion acquisition

Dr Joe Wiley, Amryt’s chief executive, said the approval was a “significant milestone” in the firm’s efforts to acquire Aegerion, which he said would strengthen the firm’s growth in “highly attractive markets”.

“This transformational deal provides Amryt with the financial flexibility to fully execute our medium-term growth plans, and is expected to deliver significant shareholder returns", the CEO added.

In an update on the acquisition back in August, Amryt said the deal would include an interim US$8mln share placing and a larger US$60mln fundraiser that will give the AIM-listed firm a pre-money valuation of US$96mln.

The merger creates a group with revenues of $136.5mln in 2018 and re-unites the Lojuxta cholesterol treatment under one roof.

In late-afternoon trading, Amryt’s shares were 10.5% higher at 116p.

Quick facts: Amryt Pharma PLC

Price: £1.34

Market: AIM
Market Cap: £67.51 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Amryt Pharma PLC named herein, including the promotion by the Company of Amryt Pharma PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Amryt Pharma's Lojuxta approved for funding as NHS treatment

David Allmond, chief commercial officer at Amryt Pharma PLC (LON:AMYT) tells Proactive Investors their Lojuxta Homozygous Familial Hypercholesterolaemia (HoFH) treatment is to be made available to NHS patients in England. HoFH is a rare life-threatening disorder that causes abnormally...

on 10/7/18

RNS

Euronext Growth Dublin Notice

2 days, 13 hours ago

Circular to Shareholders

1 week, 3 days ago

Schedule One

2 weeks, 4 days ago

Schedule One - Amryt Pharma plc

2 weeks, 4 days ago

Suspension of Trading on Euronext

2 weeks, 5 days ago

2 min read